[Is neoadjuvant chemotherapy valid in invasive cancer of the bladder?].

Urologiia i nefrologiia Pub Date : 1998-11-01
B P Matveev, K M Figurin
{"title":"[Is neoadjuvant chemotherapy valid in invasive cancer of the bladder?].","authors":"B P Matveev,&nbsp;K M Figurin","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The role of neoadjuvant chemotherapy for invasive transitional cell carcinoma (TCC) of the bladder is not determined yet. M-VAC and CMV regimens have a complete response rate of 10-47% with an overall response reaching 80%. In 16.7-35% of all the responders and 42.9-92% of the complete responders a functioning bladder can be preserved. The influence of neoadjuvant chemotherapy on long-term survival is questionable. Nevertheless, the authors conclude that neoadjuvant chemotherapy is feasible in patients with invasive TCC as it improves the results of following surgery and in some cases enables an organ sparing operation.</p>","PeriodicalId":23468,"journal":{"name":"Urologiia i nefrologiia","volume":" 6","pages":"42-5"},"PeriodicalIF":0.0000,"publicationDate":"1998-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologiia i nefrologiia","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The role of neoadjuvant chemotherapy for invasive transitional cell carcinoma (TCC) of the bladder is not determined yet. M-VAC and CMV regimens have a complete response rate of 10-47% with an overall response reaching 80%. In 16.7-35% of all the responders and 42.9-92% of the complete responders a functioning bladder can be preserved. The influence of neoadjuvant chemotherapy on long-term survival is questionable. Nevertheless, the authors conclude that neoadjuvant chemotherapy is feasible in patients with invasive TCC as it improves the results of following surgery and in some cases enables an organ sparing operation.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新辅助化疗对浸润性膀胱癌有效吗?
新辅助化疗在膀胱侵袭性移行细胞癌(TCC)中的作用尚未确定。M-VAC和CMV方案的完全缓解率为10-47%,总缓解率达到80%。16.7-35%的应答者和42.9-92%的完全应答者能保留膀胱功能。新辅助化疗对长期生存的影响尚存疑问。然而,作者得出结论,新辅助化疗在侵袭性TCC患者中是可行的,因为它改善了手术后的结果,在某些情况下可以进行器官保留手术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Effect of low-intensity laser therapy on urinary tract function]. [Statistics of oncourologic diseases in Russia in 1996]. [Experience in using laser surgery of the prostate gland in patients with a functioning pacemaker]. [Some indicators of immunity in patients with urinary stones before and after extracorporeal lithotripsy]. [Citrate therapy in treating urate nephrolithiasis].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1